• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The LRC-CPPT 1: Cholestyramine and coronary heart disease [Classics Series]

byShaidah Deghan, MSc. MDandAndrew Cheung, MD MBA
November 7, 2016
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In the 1970s, observational data suggested a direct link between serum cholesterol levels and the risk of coronary heart disease (CHD).

2. This trial was one of the first large, randomized studies to demonstrate that reducing lipid levels with cholestyramine could significantly lower death from CHD and nonfatal myocardial infarction, when compared to placebo.

Original Date of Publication: January 1984

Study Rundown: CHD remains a significant cause of death and disability around the world. In the 1970s, some observational data showed a direct relationship between serum lipid levels, particularly low-density lipoprotein cholesterol (LDL-C), and risk of CHD. It was suspected that LDL-C was heavily involved in the pathophysiology of atherosclerosis and thereby responsible for CHD. It was also understood at the time that serum lipid levels could be altered by changing diet and taking medications, though a causal relationship between cholesterol levels and CHD had yet been firmly established.

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was a large randomized trial started in the mid-1970s to address this relationship. Patients were largely high-school educated white men with elevated cholesterol levels. They were randomized to treatment with either cholestyramine or placebo, in addition to cholesterol-lowering diet and nutritional counseling. Treatment with cholestyramine led to significantly larger reductions in total cholesterol and LDL-C levels when compared to placebo therapy. Patients taking cholestryamine also experienced significantly lower rates of death from CHD and nonfatal myocardial infarction. Despite the study’s homogeneous population and limited generalizability, this was one of the first large-scale randomized trials to demonstrate a consistent reduction in CHD after lipid lowering therapy.

Click to read the study in JAMA

In-Depth [randomized double-blind controlled study]: This double-blind, placebo-controlled, randomized trial was conducted at 12 sites in the United States. Men between 35 and 59 years of age, with a plasma cholesterol level ≥6.9 mmol/L (265 mg/dL) and LDL-C level ≥4.9 mmol/L (190 mg/dL) were recruited for the study. Exclusion criteria included triglyceride levels averaging >3.387 mmol/L (300 mg/dL), type III hyperlipopriteinemia, clinical manifestations of CHD (myocardial infarction, angina pectoris, ECG abnormalities, heart failure), diabetes mellitus, hypothyroidism, nephrotic syndrome, obesity, and hypertension. A total of 3806 participants were randomized to treatment with either cholestyramine 24 g daily or an equivalent amount of placebo and followed for an average of 7.4 years. All patients were offered a cholesterol-lowering diet along with nutritional counseling. The primary endpoint was a composite of death from CHD and nonfatal myocardial infarction. Other endpoints were all-cause mortality, atherothrombotic brain infarction, and arterial peripheral vascular disease.

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

Compared to placebo, treatment with cholestyramine significantly reduced total cholesterol (8.5%, p < 0.001) and LDL-C (12.6%, p < 0.001). At 7 years, the primary endpoint occurred significantly less frequently in the cholestyramine group as compared with the placebo group (8.1% vs. 9.8%; risk reduction 19%, 90%CI 3 to 32%, p < 0.05). There were significantly fewer CHD deaths (1.6% vs. 2.0%; risk reduction 24%) and nonfatal myocardial infarctions (6.8% vs. 8.3%; risk reduction 19%) in patients taking cholestyramine. There were no significant differences between the two groups in the incidence of brain infarction or peripheral vascular disease, and no difference in all-cause mortality. Gastrointestinal side effects were common during the trial. In the first year, the rate of such side effects were significantly higher in the cholestyramine group (68% vs. 43%). These rates were quite similar by year 7 (29% vs. 26%).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: cholesterolcoronary heart diseaselrc-cpptlrc-cppt 1
Previous Post

Psychotropic medications reduce further violent crimes in released prisoners

Next Post

Flavored e-cigarette use associated with higher smoking risks in youth

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors
StudyGraphics

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

July 15, 2021
Shorter time to angioplasty may improve heart attack outcomes
Cardiology

ST-elevation myocardial infarctions in the absence of standard modifiable cardiovascular risk factors may have worse outcomes

June 25, 2021
Next Post

Flavored e-cigarette use associated with higher smoking risks in youth

Unmet healthcare need in adolescence linked to poor adult outcomes

Therapy advancements not correlated with improved health status for adult survivors of childhood cancer

Decreased prevalence of HPV among vaccinated young females

State legislation linked to increase in HPV vaccination in teenage girls

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.